Pharmaceutical companies can continue to charge the federal government—and Medicare beneficiaries—full price for a handful of drugs that might have seen price reductions as...
OpenAI’s latest flagship artificial intelligence model, GPT-5, has drawn mixed reviews in China, where some critics expressed disappointment over the new system’s lack of...
Beijing should be vigilant about India’s recent moves to strengthen infrastructure in a disputed border area while setting its own pace for China’s development...